Redmile Group’s Quest Diagnostics DGX Stock Holding History

Redmile Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-83,849	Closed	-$11.2M	–	68
2024 Q1	$11.2M	Buy	+83,849	New	+$10.9M	0.41%	54

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Redmile Group's DGX Position: Q2 2024 in Review

Redmile Group sold out of Quest Diagnostics (DGX) in Q2 2024, closing a stake of 83,849 shares — an estimated $11.2M sold.

Redmile Group first reported a position in DGX in Q1 2024 and held it in 1 quarter. The position peaked at $11.2M in Q1 2024. 838 funds tracked by Wall St. Rank hold DGX as of Q2 2024.

Redmile Group reported no remaining Quest Diagnostics position as of Q2 2024 after selling out during the quarter.
Redmile Group sold 83,849 Quest Diagnostics shares in Q2 2024, an estimated $11.2M.
Redmile Group first reported a position in Quest Diagnostics in Q1 2024 and held it in 1 quarter.
Redmile Group's Quest Diagnostics position peaked at $11.2M in Q1 2024.
838 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2024.

Based on Redmile Group's 13F filing for Q2 2024, filed 14 Aug 2024.